Abstract P056: Polθ inhibitors elicit <i>BRCA</i>-gene synthetic lethality and target PARP inhibitor resistance
Diana Zatreanu(Institute of Cancer Research), Christopher J. Lord(Institute of Cancer Research), Helen M.R. Robinson, Jayne Curry(Brigham and Women's Hospital), Theresia A. Schaedler(University of Cambridge), S.J. Pettitt(Institute of Cancer Research), Joana Neves, Rachel Brough(Institute of Cancer Research), Tennyson Ekwuru(Cancer Research UK), Rebecca Marlow(Institute of Cancer Research), Vera Grinkevich(Wellcome Sanger Institute), Graeme Hewitt(Newcastle Hospitals - Campus for Ageing and Vitality), Cameron Bell(Cancer Research UK), Marco Ranzani(Wellcome Sanger Institute), Niall M.B. Martin, Elsa Callén(National Cancer Institute), R H Heald, André Nussenzweig(National Institutes of Health), Martin L. Stockley, Marie Boursier, Remko Prevo(University of Oxford), Joost Schimmel(Leiden University Medical Center), Jayesh B. Majithiya, Eleanor Knight(Cancer Research UK), Katherine Ewings(Babraham Institute), Lerin Geo, Peter Blencowe(Cancer Research UK), Sophie Langdon(King's College London), Syed Haider(MRC Laboratory of Molecular Biology), Aditi Gulati(Institute of Cancer Research), Christina Alli(Cancer Research UK), Mathew Calder(Cancer Research UK), Kimberley A. Wiggins, Marcel Tijsterman(Leiden University), Eeson Rajendra(Pharma Nord (United Kingdom)), Luned Badder(Cardiff University), Omar Alkhatib, Mark Charles(Cancer Research UK), Geoff S. Higgins(Oxford University Hospitals NHS Trust), Harry Finch(University of Liverpool), Amanda Ferdinand(Cancer Research UK), Graeme C.M. Smith(Acacia Pharma (United Kingdom)), Daniela Novo(Breast Cancer Research Foundation), Andrew Tutt(Institute of Cancer Research), Nan Shao(The First People's Hospital of Changzhou), Simon J. Boulton(The Francis Crick Institute), Sandhya Sridhar(Institute of Cancer Research), Diego Grande, Shaun Moore, Claire McWhirter(AstraZeneca (United Kingdom))
Cited by 3
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k